Current issue: 2017 

Special Issue

Living Donor Liver Transplantation: Worldwide Evolution and Unmet Need

Submission Deadline: December 30, 2017 (Open)                Submit Now

Guest Editor

Dimitrios E. Giakoustidis, MD, PhD
Associate Professor of Surgery and Transplantation, Division of Transplant Surgery, Department of Surgery, Aristotle University, Hippokration General Hospital Thessaloniki, Greece
Research Interests: surgical oncology; liver surgery; liver transplantation; pancreatic cancer; hcc and hcc signaling, etc


Luca Toti, MD, PhD
Assistant Professor of Surgery and Transplantation, Department of Experimental Medicine and Surgery, Section of Transplantation, University of Rome Tor Vergata, Rome, Italy

Naimish N. Mehta, MD, PhD
Chief Liver Transplant Surgeon, Senior Consultant G.I & HPB Surgery, Convenor Gyan Burman Hepato-Biliary Fellowship, R. No. 2222, Department of Surgical GI & Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, India

About This Topic

Shortage of cadaveric donors represents a major obstacle to liver transplantation worldwide. Furthermore, the number of patients being listed for this procedure is increasing, while the number of donors remains stable. Consequently, more and more patients are dying while still on the waiting list.

Living donor liver transplantation (LDLT) is performed in both adults and children. Adult-to-adult LDLT has been developed and established primarily in Asian countries. Given the comparatively greater availability of deceased donors in Western countries, LDLT comprises a much lower percentage of transplantations compared with that in Asian countries. This has a significant impact on recipients who are currently disadvantaged by the Model for End-Stage Liver Disease (MELD)-based system of liver allocation and in some countries, the low percentage of deceased donors.

In recent years, there have been significant advances in surgical techniques. Laparoscopic or robotic harvesting of the liver, dual grafts, vein reconstruction, enhanced recovery protocols, and intra-operative bleeding control, are important issues in the field of liver transplantation. Improvements in immunosuppression, novel anti-hepatitis C drugs and hepatocellular carcinoma-targeted therapies could improve the outcome and survival of transplanted patients.

In this special issue, we welcome manuscripts concerning all current and novel knowledge in the field of living donor liver transplantation.